Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure
NCT: NCT02592499 · ACTIVE_NOT_RECRUITING
Brief Summary
The study is a prospective, randomized, non-blinded, national, multi-center study. The study will consist of the assignment of eligible patients to treatment with either a HeartMate III (HM III) left ventricular assist device system or to pharmacological treatment (optimal medical management, OMM) according to current guidelines. Eighty (80) patients will be enrolled in this study and randomized in a 1:1 fashion between the HM III and OMM, based on a modified power calculation.
Frequently Asked Questions
What is Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure?
Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure is a clinical trial registered under NCT02592499. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT02592499?
The current status of NCT02592499 (Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure) is: ACTIVE_NOT_RECRUITING.
When did Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure start?
Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure started on 2016-06.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.